NXGL logo

NEXGEL (NXGL) Company Overview

Profile

Full Name:

NEXGEL, Inc.

Sector:

Healthcare

Country:

United States

IPO:

December 22, 2021

Indexes:

Not included

Description:

NexGel Inc. specializes in developing and manufacturing innovative hydrogel products for various applications, including medical, personal care, and consumer markets. Their focus is on creating advanced materials that enhance comfort and performance, particularly in wound care and skincare solutions.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 25, 22 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
NXGL
globenewswire.comJanuary 2, 2025

LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant.

NEXGEL Announces $2,000,000 Registered Direct Offering
NEXGEL Announces $2,000,000 Registered Direct Offering
NEXGEL Announces $2,000,000 Registered Direct Offering
NXGL
globenewswire.comNovember 11, 2024

LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance.

NEXGEL to Participate in Upcoming October Investor Conferences
NEXGEL to Participate in Upcoming October Investor Conferences
NEXGEL to Participate in Upcoming October Investor Conferences
NXGL
globenewswire.comOctober 11, 2024

LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences.

NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
NXGL
globenewswire.comOctober 4, 2024

LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board.

NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
NXGL
globenewswire.comAugust 14, 2024

LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively.

NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
NXGL
globenewswire.comAugust 12, 2024

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.

NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
NXGL
globenewswire.comJuly 18, 2024

The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments

NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
NXGL
globenewswire.comJuly 8, 2024

LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024.

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
NXGL
globenewswire.comJune 11, 2024

LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe's number one selling Diamine Oxidase (‘DAO') enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin conditions. Headquartered in Germany, STADA is one of the fastest growing top ten companies in consumer healthcare and the fourth largest manufacturer in this segment in Europe.

NEXGEL Acquires International Beauty Brand, Silly George
NEXGEL Acquires International Beauty Brand, Silly George
NEXGEL Acquires International Beauty Brand, Silly George
NXGL
globenewswire.comMay 16, 2024

The acquisition of Silly George expands NEXGEL's consumer product portfolio in Health, Wellness, and Beauty. Silly George is currently generating around $2 million in revenue.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for NEXGEL?
  • Does NEXGEL pay dividends?
  • What sector is NEXGEL in?
  • What industry is NEXGEL in?
  • What country is NEXGEL based in?
  • When did NEXGEL go public?
  • Is NEXGEL in the S&P 500?
  • Is NEXGEL in the NASDAQ 100?
  • Is NEXGEL in the Dow Jones?
  • When does NEXGEL report earnings?
  • Should I buy NEXGEL stock now?

What is the ticker symbol for NEXGEL?

The ticker symbol for NEXGEL is NASDAQ:NXGL

Does NEXGEL pay dividends?

No, NEXGEL does not pay dividends

What sector is NEXGEL in?

NEXGEL is in the Healthcare sector

What industry is NEXGEL in?

NEXGEL is in the Medical Instruments & Supplies industry

What country is NEXGEL based in?

NEXGEL is headquartered in United States

When did NEXGEL go public?

NEXGEL's initial public offering (IPO) was on December 22, 2021

Is NEXGEL in the S&P 500?

No, NEXGEL is not included in the S&P 500 index

Is NEXGEL in the NASDAQ 100?

No, NEXGEL is not included in the NASDAQ 100 index

Is NEXGEL in the Dow Jones?

No, NEXGEL is not included in the Dow Jones index

When does NEXGEL report earnings?

The date for NEXGEL's next earnings report has not been announced yet

Should I buy NEXGEL stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions